PUBLISHER: DelveInsight | PRODUCT CODE: 1462306
PUBLISHER: DelveInsight | PRODUCT CODE: 1462306
"Olpasiran Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about olpasiran for myocardial infarction in the seven major markets. A detailed picture of the olpasiran for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the olpasiran for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the olpasiran market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.
Olpasiran (formerly AMG 890) is a small interfering RNA designed to lower the body's production of apolipoprotein (a), a key component of Lp (a) that has been associated with an increased risk of cardiovascular events.
In November 2022, the company presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran in adults with elevated lipoprotein (a) [Lp (a)] levels (>150 nmol/L) and a history of atherosclerotic cardiovascular disease (ASCVD) during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2022, and simultaneously published in the New England Journal of Medicine. The company is currently conducting a Phase III trial with data expected by 2027.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Olpasiran Analytical Perspective by DelveInsight
This report provides a detailed market assessment of olpasiran for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.
The report provides the clinical trials information of olpasiran for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.